DE112011102409T5 - Verfahren zur Behandlung der Alzheimer-Krankheit - Google Patents

Verfahren zur Behandlung der Alzheimer-Krankheit Download PDF

Info

Publication number
DE112011102409T5
DE112011102409T5 DE112011102409T DE112011102409T DE112011102409T5 DE 112011102409 T5 DE112011102409 T5 DE 112011102409T5 DE 112011102409 T DE112011102409 T DE 112011102409T DE 112011102409 T DE112011102409 T DE 112011102409T DE 112011102409 T5 DE112011102409 T5 DE 112011102409T5
Authority
DE
Germany
Prior art keywords
activated
antibody
potentiated
synthase
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112011102409T
Other languages
German (de)
English (en)
Inventor
Anmelder Gleich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44863153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE112011102409(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Application filed by Individual filed Critical Individual
Publication of DE112011102409T5 publication Critical patent/DE112011102409T5/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE112011102409T 2010-07-21 2011-07-15 Verfahren zur Behandlung der Alzheimer-Krankheit Withdrawn DE112011102409T5 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2010130353 2010-07-21
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127058 2011-07-01
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
PCT/IB2011/002434 WO2012010978A2 (en) 2010-07-21 2011-07-15 A method of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
DE112011102409T5 true DE112011102409T5 (de) 2013-07-04

Family

ID=44863153

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112011102409T Withdrawn DE112011102409T5 (de) 2010-07-21 2011-07-15 Verfahren zur Behandlung der Alzheimer-Krankheit

Country Status (16)

Country Link
US (1) US20130058982A1 (https=)
EP (1) EP2596021A2 (https=)
JP (1) JP2013535445A (https=)
CN (1) CN103119060A (https=)
AU (1) AU2011281252A1 (https=)
CA (1) CA2805943A1 (https=)
DE (1) DE112011102409T5 (https=)
EA (1) EA029399B1 (https=)
FR (1) FR2962912A1 (https=)
GB (1) GB2496801B (https=)
IT (1) ITTO20110633A1 (https=)
MX (1) MX2013000808A (https=)
NZ (1) NZ606969A (https=)
PH (1) PH12013500143A1 (https=)
UA (1) UA107836C2 (https=)
WO (1) WO2012010978A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
PH12013500107A1 (en) * 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
EP2593474A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP2593477A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
JP2013536174A (ja) * 2010-07-21 2013-09-19 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物並びに回転性めまい、動揺病及び自律神経血管ジストニアを治療する方法
EA029199B1 (ru) 2010-07-21 2018-02-28 Олег Ильич Эпштейн Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
CN104324359B (zh) * 2014-09-25 2016-08-17 中山大学 Rry三肽在制备治疗阿尔茨海默症药物中的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BRPI0601496B8 (pt) * 2006-04-13 2021-05-25 Miria De Amorim composições medicamentosas, uso das mesmas, kits medicamentosos e método de aplicação das composições medicamentosas
JP2013536174A (ja) * 2010-07-21 2013-09-19 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物並びに回転性めまい、動揺病及び自律神経血管ジストニアを治療する方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Hum. Antibodies. Monoclonal and recombinant antibodies, 30 years alter" von Laffly E., Sodoyer R. - 2005 - Bd. 14. - N 1-2. S. 33-55
Castagne V. et al., Antibodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat (Antikörper gegen S100-Proteine haben anxiolytisch-ähnliche Aktivität bei ultraniedrigen Dosen in der erwachsenen Ratte), J Pharm Pharmacol. 2008, 60(3): 309-16
Epshtein O. I., Antibodies to calcium-binding S100B protein block the conditioning of long-term sensitization in the terrestrial snail (Antikörper gegen Calcium-bindendes S100B-Protein blockieren die Konditionierung von langfristiger Sensibilisierung in der terrestrischen Schnecke), Pharmacol Biochem Behav., 2009, 94(1): 37-42
G. Frimel, M., "Meditsyna", 1987, S. 9-33
Habib et al., Nitric Oxide Measurement From Blood To Lungs, Is There A Link? (Stickstoffmonoxid-Messung vom Blut bis zu den Lungen. Gibt es eine Verbindung?) Pak J Physiol 2007; 3(1)
M. B. Shtark, Brain-Specific Protein Antigenes and Functions of Neuron, "Medicine", 1985; S. 12-14
M. V. Starostin, S. M. Sviridov, Neurospecific Protein S-100, Progress of Modern Biology, 1977, Bd. 5, S. 170-178
V. Schwabe "Homeopathic medicines", M., 1967, S. 14-29
Voronina T. A. et al., Kapitel B. Antibodies to S-100 protein in anxiety-depressive disorders in experimental and clinical conditions (Antikörper gegen S-100-Protein bei Angst-depressiven Störungen unter experimentellen und klinischen Bedingungen), in: "Animal models in biological psychiatry"; Hrsg. Kalueff A. V. N-Y, "Nova Science Publishers, Inc.", 2006, S. 137-152
Yardan et al., Usefulness of S100B Protein in Neurological Disorders, J Pak Med Assoc, Bd. 61, Nr. 3, März 2011

Also Published As

Publication number Publication date
MX2013000808A (es) 2013-10-28
JP2013535445A (ja) 2013-09-12
CA2805943A1 (en) 2012-01-26
GB2496801B (en) 2018-04-11
WO2012010978A3 (en) 2012-04-26
CN103119060A (zh) 2013-05-22
PH12013500143A1 (en) 2019-09-02
GB2496801A (en) 2013-05-22
AU2011281252A1 (en) 2013-03-07
EA201300130A1 (ru) 2013-12-30
GB201302929D0 (en) 2013-04-03
UA107836C2 (uk) 2015-02-25
US20130058982A1 (en) 2013-03-07
NZ606969A (en) 2015-08-28
WO2012010978A2 (en) 2012-01-26
EP2596021A2 (en) 2013-05-29
EA029399B1 (ru) 2018-03-30
ITTO20110633A1 (it) 2012-01-22
FR2962912A1 (fr) 2012-01-27

Similar Documents

Publication Publication Date Title
DE112011102409T5 (de) Verfahren zur Behandlung der Alzheimer-Krankheit
DE112011102355T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes
DE112011102362T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen
DE112011102411T5 (de) Verfahren zur Behandlung von Aufmerksamkeits-Mangel-Hyperaktivitäts-Störung
DE69405102T2 (de) Antikoerperfragmente in therapie
DE112011102349T5 (de) Pharmazeutische Zusammensetzung und Behandlungsverfahren
DE112011102640T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung undPrävention von Infektionskrankheiten
DE112011102638T5 (de) Pharmazeutische Zusammensetzung und Verfahren zur Behandlung und Prävention der Krankheiten, die durch HIV verursacht werden oder mit HIV zusammenhängen
EP0804236A1 (de) Verwendung von anti-tnf-antiköpern als arzneimittel zur behandlung von erkrankungen mit einem erhöhten interleukin-6 serumspiegel
US20120258146A1 (en) Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy
DE112011102412T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von mit Atemwegserkrankungen bzw. Atemwegsleiden assoziierten Erkrankungen bzw. Leiden
DE112011102397T5 (de) Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie
DE112011102350T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems
DE112011102639T5 (de) Pharmazeutische Zusammensetzung und Verfahren zur Hemmung der Erzeugung oder zur Verstärkung der Eliminierung von P24-Protein
DE112011102649T5 (de) Medikament und Verfahren zur Prävention einer HIV-Kontamination, Prävention und Behandlung von Krankheiten, die durch HIV verursacht werden, und von mit HIV zusammenhängen-den Krankheiten, einschließlich AIDS
DE112011102358T5 (de) Verfahren zur Erhöhung der Wirkung einer aktivierten-potenzierten Form eines Antikörpers
DE69416601T2 (de) Verwendung von antiidiotypischen antikörpern zur vorbeugung einer hyperakuten abstossung von xenotransplantaten
RU2536234C2 (ru) Нейротропное лекарственное средство и способ лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза
RU2536232C2 (ru) Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2542445C2 (ru) Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
DE112014001508T5 (de) Verfahren zur Bestimmung des Grads der modifizierten Wirksamkeit eines Medikaments
DE2347628C3 (de) Verfahren zur Gewinnung immunsuppressiver Gammaglobuline und Verwendung der Gammaglobuline zur Behandlung der Implanat-Abstoflung und von Autoaggressionskrankheiten
DE3720232A1 (de) Verfahren zur herstellung eines extraktes aus aloe-blaettern der pflanzengattung aloe capensis oder aloe arborescens
DE69328605T2 (de) Antikörper enthaltende Arzneimittelzusammensetzung gegen AIDS
EP0161404B1 (de) Verfahren zur Herstellung von künstlichen biomimetischen Haptenen bzw. Antigenen

Legal Events

Date Code Title Description
R079 Amendment of ipc main class

Free format text: PREVIOUS MAIN CLASS: A61K0039395000

Ipc: C07K0016180000

R012 Request for examination validly filed

Effective date: 20140512

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee